Gomes U C, Cleland J G
Cardio.net Editorial Office, Macclesfield, Cheshire, UK.
Eur J Heart Fail. 1999 Aug;1(3):301-2. doi: 10.1016/s1388-9842(99)00040-9.
The RUSSLAN study, which randomised 504 patients with post-infarction heart failure in whom intravenous inotropic support might be deemed appropriate, was presented for the first time in a hotline session at the annual meeting of the Working Group on Heart Failure of the European Society of Cardiology. The study suggested that levosimendan, a new calcium sensitising agent, could be used safely in patients with post-infarction heart failure in the absence of severe hypotension and that it appeared to improve symptoms and survival. If these results can be confirmed it would render it unique among intravenous inotropic agents.
RUSSLAN研究首次在欧洲心脏病学会心力衰竭工作组年度会议的热线会议上公布，该研究将504例可能适合静脉使用正性肌力支持的心肌梗死后心力衰竭患者进行了随机分组。研究表明，新型钙增敏剂左西孟旦可在无严重低血压的心肌梗死后心力衰竭患者中安全使用，且似乎能改善症状和提高生存率。如果这些结果能得到证实，它将成为静脉正性肌力药物中的独特药物。
